Eyevance
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $30.0m | Early VC | |
* | $225m Valuation: $225m | Acquisition | |
Total Funding | €27.3m |
Related Content
Recent News about Eyevance
EditEyevance Pharmaceuticals specializes in developing innovative and impactful ophthalmic therapies focused on the ocular surface and anterior segment. The company aims to revolutionize eye care by providing affordable medications and cutting-edge technologies that address significant unmet needs. Eyevance serves a diverse range of clients, including healthcare providers and patients, primarily in the ophthalmology market. The business model revolves around the development, marketing, and sale of its proprietary eye care products. Revenue is generated through product sales and strategic partnerships, such as the recent acquisition by Santen Pharmaceuticals. Eyevance is committed to continuous learning, growth, and collaboration with customers to ensure the highest quality of care.
Keywords: ophthalmic therapies, ocular surface, anterior segment, eye care, innovative solutions, affordable medication, healthcare providers, product pipeline, strategic partnerships, Santen Pharmaceuticals.